- |||||||||| Clinical, Review, Journal: Intermittent use of biologic agents for the treatment of psoriasis in adults. (Pubmed Central) - May 15, 2021
The exception to these general findings was infliximab, which showed the lowest rate of efficacy-endpoint achievement (25% and 38% in two dosing groups evaluated) as well as a higher incidence of adverse infusion reactions compared with continuous dosing. In conclusion, the use of biologic agents in psoriasis is changing and current clinical data suggest that intermittent treatment may provide an effective and well tolerated option for certain patients.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Serum Krebs von den Lungen-6 levels in psoriatic patients under treatment with biologics. (Pubmed Central) - May 15, 2021 The 26 anti-IL-17 treatments consisted of nine secukinumab, six ixekizumab and 11 brodalumab...In addition to the influence of IFX, a significantly large number of patients in the IFX group had a history of methotrexate administration associated with psoriatic arthritis, which might have influenced the KL-6 level. None of the patients with elevated serum KL-6 showed pulmonary changes by computed tomography and/or X ray.
- |||||||||| Journal: EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. (Pubmed Central) - May 15, 2021
It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.
- |||||||||| Tremfya (guselkumab) / J&J
Clinical, Journal: Effects of guselkumab on ankylosing spondylitis-type pustulotic arthro-osteitis in a patient with palmoplantar pustulosis. (Pubmed Central) - May 15, 2021 The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. No abstract available
- |||||||||| Stelara (ustekinumab) / J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] Racial and Ethnic Disparities in COVID-19-Related Infection in Patients with Psoriasis: A Cross-Sectional Study () - May 4, 2021 - Abstract #SID2021SID_860; No significant differences were seen in infection, hospitalization, or mortality rates between non-Hispanic races (Caucasian, African American, and Asian). Overall, psoriasis patients did not have increased risk for COVID-19 infection, hospitalization, or mortality, regardless of treatment modality.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Eucrisa (crisaborole) / Pfizer
[VIRTUAL] Update on Scalp, Nail, and Inverse Psoriasis: Symposium for Inflammatory Skin Disease 2021® Highlights () - Apr 29, 2021 - Abstract #DERFISDS2021DERF_ISDS_21; Ixekizumab is the only biologic with genital psoriasis data as part of its FDA label...For acutely ill patients, first considerations should include cyclosporine, infliximab, and the IL-17 inhibitors. For more subacute erythroderma, one may consider the anti-TNF agents, anti-IL23 agents, or anti-IL-12/23 agent, as well as nonbiologic agents including methotrexate and acitretin.
- |||||||||| Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
[VIRTUAL] ECONOMIC IMPACT OF FAILED BIOLOGIC LOADING PERIODS FOR PSORIASIS PATIENTS () - Apr 11, 2021 - Abstract #AMCP2021AMCP_150; Published costs of the most widely prescribed biologics (i.e., adalimumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, risankizumab) were cross-referenced with published efficacy rates, demonstrating the amount of spend that is wasted per biologic on an individual patient who does not respond during the initial loading period. This study has important implications on the need for individualized pharmacogenomic prediction before prescription and expensive failed loading periods.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
[VIRTUAL] Sustained Improvement in General Health-Related Quality of Life and Work Productivity in Patients with Moderate to Severe Psoriasis Treated with Guselkumab: 5-Year Data from Clinical Trial VOYAGE 2 () - Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_801; Background: In VOYAGE-2, greater improvements in measures of HRQoL, depression and anxiety, and work productivity were achieved in GUS-treated patients vs placebo(PBO;Wk16) and vs adalimumab(ADA;Wk24).1,2,3 Results from Wks100-252(5-years) are presented. Patients with moderate-to-severe PsO sustained improvements in general HRQoL, depression and anxiety, and work productivity through up to 5-years of GUS.
- |||||||||| [VIRTUAL] Cumulative Clinical Benefits of Biologic Treatments for Psoriasis over 1 Year () - Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_617;
Data for biologic therapies included in this analysis (adalimumab, brodalumab, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, ustekinumab) were obtained from published phase 3 clinical trials of biologics approved for psoriasis, and analyzed by network meta-analysis at 1 year using published methodology.[1] Total cumulative benefit from weeks 0-52 was estimated using the area-under-curve (AUC) method.[2-4] The cumulative benefits for each treatment were normalized as a percentage of maximum possible AUC. IL-17 inhibitors ixekizumab and brodalumab and the IL-23 inhibitor risankizumab offer long-term cumulative clinical benefits when the treatment goal is complete skin clearance.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie, Tremfya (guselkumab) / J&J
[VIRTUAL] Maintaining Long-term Improvements in Patient-reported Symptoms, Signs, and Quality of Life Among Patients with Moderate to Severe Plaque Psoriasis Treated with Guselkumab: VOYAGE 2, 5-Year Data () - Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_593; Patients were randomized to GUS 100mg at Wks0/4/12, then every-8-wks(q8w); placebo(PBO), then GUS at Wks16/20, then q8w; or adalimumab(ADA) 80mg at Wk0, 40mg at Wk1, then 40mg q2w through Wk23. GUS treatment through up to 5-years stably maintained improvement in patient-reported symptoms, signs and HRQoL in patients with moderate-to-severe PsO.
- |||||||||| [VIRTUAL] Comparative Efficacy of Treatments for Moderate-to-Severe Plaque Psoriasis: An Updated Network Meta-Analysis (NMA) () - Apr 10, 2021 - Abstract #AADVMX2021AAD_VMX_251;
In the short term (N=69 RCTs), the PASI 90 rates were highest for ixekizumab (72.9%), risankizumab (72.9%), and brodalumab (72.3%), which were significantly higher than guselkumab (65.4%), secukinumab (65.4%), infliximab (56.4%), certolizumab (400 mg: 49.8%, 200 mg: 42.4%), ustekinumab (46.2%), adalimumab (44.2%), tildrakizumab (200 mg: 40.0%, 100 mg: 37.4%), etanercept (18.0%), dimethyl fumarate (12.8%), and apremilast (12.6%). Ixekizumab, risankizumab, and brodalumab had the highest short-term efficacy, and risankizumab had the highest long-term efficacy.
|